IMRX
Immuneering Corporation NASDAQ Listed Jul 30, 2021$4.76
+5.08%
vs $4.53
Mkt Cap $209.5M
52w Low $3.04
27.7% of range
52w High $9.26
50d MA $4.97
200d MA $5.75
P/E (TTM)
—
EV/EBITDA
—
P/B
1.0x
Debt/Equity
0.0x
ROE
-25.6%
P/FCF
-4.6x
RSI (14)
64.30
ATR (14)
$0.28
Beta
0.43
50d MA
$4.97
200d MA
$5.75
Avg Volume
2.2M
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
CIK (SEC)
Phone
617 500 8080
245 Main Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | AMC | -0.30 | -0.21 | +30.0% | 5.16 | -1.7% | -5.6% | +0.4% | +2.7% | +4.0% | +3.3% | — |
| Mar 6, 2026 | AMC | -0.31 | -0.18 | +41.9% | 5.33 | -2.1% | +5.4% | +0.0% | +0.5% | -3.5% | -7.3% | — |
| Nov 12, 2025 | AMC | -0.37 | -0.38 | -2.7% | 6.62 | +3.0% | -2.6% | -1.6% | +9.0% | +3.3% | +0.3% | — |
| Aug 13, 2025 | AMC | -0.40 | -0.40 | +0.0% | 3.22 | -1.2% | -5.6% | +23.7% | -6.9% | -4.3% | +2.4% | — |
| May 5, 2025 | AMC | -0.41 | -0.42 | -2.4% | 1.25 | +1.6% | -4.8% | -7.6% | +8.2% | -4.2% | +4.4% | — |
| Mar 20, 2025 | AMC | -0.42 | -0.58 | -38.1% | 1.65 | -7.9% | +9.1% | -3.3% | -2.9% | -3.0% | +1.2% | — |
| Nov 13, 2024 | AMC | -0.54 | -0.49 | +9.3% | 1.71 | +8.8% | +13.5% | -7.2% | +0.0% | +13.3% | +0.0% | — |
| Aug 6, 2024 | AMC | -0.51 | -0.47 | +7.8% | 1.24 | -4.0% | -8.1% | -1.8% | -2.7% | +4.6% | +0.0% | — |
| May 7, 2024 | AMC | -0.45 | -0.49 | -8.9% | 1.56 | -0.6% | +4.5% | -4.3% | -7.1% | +9.7% | +0.6% | — |
| Mar 1, 2024 | AMC | -0.48 | -0.52 | -8.3% | 6.15 | +24.9% | +0.0% | +0.8% | +3.2% | +4.4% | -1.8% | — |
| Nov 9, 2023 | AMC | -0.51 | -0.43 | +15.7% | 5.20 | +2.5% | -0.3% | -6.7% | +8.8% | +0.3% | -2.7% | — |
| Aug 3, 2023 | AMC | -0.54 | -0.43 | +20.4% | 10.25 | +0.3% | +1.9% | -5.9% | +1.8% | +0.0% | +0.0% | — |
| May 4, 2023 | AMC | -0.54 | -0.51 | +5.6% | 8.03 | +1.7% | -0.6% | -9.3% | +7.9% | -7.9% | +3.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9 | Needham | Maintains | Buy → Buy | — | $5.33 | $5.22 | -2.1% | +5.4% | +0.0% | +0.5% | -3.5% | -7.3% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $6.62 | $6.82 | +3.0% | -2.6% | -1.6% | +9.0% | +3.3% | +0.3% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.75 | $6.94 | +2.8% | +3.7% | -9.1% | +2.7% | -7.4% | +3.8% |
| Sep 26 | Chardan Capital | Maintains | Buy → Buy | — | $8.00 | $8.18 | +2.2% | +1.0% | -16.5% | +3.7% | -9.1% | +2.7% |
| Sep 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.23 | $9.59 | +3.9% | -13.3% | +1.0% | -16.5% | +3.7% | -9.1% |
| Sep 15 | Needham | Maintains | Buy → Buy | — | $8.49 | $8.62 | +1.5% | -7.4% | +5.7% | -2.9% | +11.6% | +2.8% |
| Aug 26 | Needham | Maintains | Buy → Buy | — | $5.95 | $6.00 | +0.8% | -0.5% | -12.3% | +7.9% | +2.7% | +4.2% |
| Aug 14 | Chardan Capital | Maintains | Buy → Buy | — | $3.22 | $3.18 | -1.2% | -5.6% | +23.7% | -6.9% | -4.3% | +2.4% |
| Jun 18 | Needham | Maintains | Buy → Buy | — | $1.82 | $2.07 | +13.7% | +52.2% | -7.6% | -4.7% | +20.5% | +2.7% |
| Jun 18 | Mizuho | Maintains | Outperform → Outperform | — | $1.82 | $2.07 | +13.7% | +52.2% | -7.6% | -4.7% | +20.5% | +2.7% |
| Jun 18 | Chardan Capital | Maintains | Buy → Buy | — | $1.82 | $2.07 | +13.7% | +52.2% | -7.6% | -4.7% | +20.5% | +2.7% |
| Jun 5 | Needham | Maintains | Buy → Buy | — | $1.96 | $2.01 | +2.6% | +4.6% | +3.9% | +1.9% | +0.0% | -2.3% |
| May 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.19 | $1.24 | +4.2% | -7.6% | +8.2% | -4.2% | +4.4% | +7.6% |
| May 6 | Chardan Capital | Maintains | Buy → Buy | — | $1.25 | $1.27 | +1.6% | -4.8% | -7.6% | +8.2% | -4.2% | +4.4% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $1.29 | $1.28 | -0.8% | -3.9% | +4.0% | +0.8% | -0.8% | -3.1% |
| Mar 24 | Chardan Capital | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | -3.3% | -2.9% | -3.0% | +1.2% | -1.2% |
| Mar 21 | Needham | Maintains | Buy → Buy | — | $1.65 | $1.52 | -7.9% | +9.1% | -3.3% | -2.9% | -3.0% | +1.2% |
| Feb 6 | Needham | Maintains | Buy → Buy | — | $1.91 | $1.97 | +3.1% | +4.2% | -4.5% | -2.1% | -3.2% | +1.1% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $2.07 | $2.04 | -1.4% | -2.9% | -3.0% | -2.6% | +3.2% | +3.1% |
| Jan 8 | Chardan Capital | Maintains | Buy → Buy | — | $2.36 | $2.14 | -9.3% | -15.3% | +3.5% | -2.9% | -3.0% | -2.6% |
| Jan 7 | Needham | Maintains | Buy → Buy | — | $2.36 | $3.74 | +58.5% | +0.0% | -15.3% | +3.5% | -2.9% | -3.0% |
| Nov 20 | Chardan Capital | Maintains | Buy → Buy | — | $2.04 | $2.04 | +0.0% | +0.0% | +3.4% | -0.5% | -1.0% | -1.4% |
| Nov 14 | Needham | Maintains | Buy → Buy | — | $1.71 | $1.86 | +8.8% | +13.5% | -7.2% | +0.0% | +13.3% | +0.0% |
| Sep 13 | Needham | Maintains | Buy → Buy | — | $1.43 | $2.09 | +46.2% | +41.3% | +42.1% | -3.1% | -18.0% | +6.1% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $1.24 | $1.19 | -4.0% | -8.1% | -1.8% | -2.7% | +4.6% | +0.0% |
| Aug 7 | Chardan Capital | Maintains | Buy → Buy | — | $1.24 | $1.19 | -4.0% | -8.1% | -1.8% | -2.7% | +4.6% | +0.0% |
| May 8 | Needham | Maintains | Buy → Buy | — | $1.56 | $1.55 | -0.6% | +4.5% | -4.3% | -7.1% | +9.7% | +0.6% |
| Apr 12 | Needham | Maintains | Buy → Buy | — | $2.08 | $2.08 | +0.0% | +1.0% | -8.6% | -4.2% | +1.1% | -4.8% |
| Apr 2 | Mizuho | Maintains | Buy → Buy | — | $2.75 | $2.72 | -1.1% | -9.1% | -4.0% | -2.1% | -6.8% | -3.2% |
| Mar 15 | TD Cowen | Downgrade | Outperform → Market Perform | — | $2.90 | $2.82 | -2.8% | -34.1% | +34.0% | +0.4% | +8.2% | -1.8% |
| Mar 15 | Needham | Maintains | Buy → Buy | — | $2.90 | $2.82 | -2.8% | -34.1% | +34.0% | +0.4% | +8.2% | -1.8% |
| Mar 15 | Chardan Capital | Maintains | Buy → Buy | — | $2.90 | $2.82 | -2.8% | -34.1% | +34.0% | +0.4% | +8.2% | -1.8% |
| Mar 15 | Jefferies | Downgrade | Buy → Hold | — | $2.90 | $2.82 | -2.8% | -34.1% | +34.0% | +0.4% | +8.2% | -1.8% |
| Mar 14 | Guggenheim | Downgrade | Buy → Neutral | — | $5.88 | $4.64 | -21.1% | -50.7% | -34.1% | +34.0% | +0.4% | +8.2% |
| Mar 11 | Needham | Maintains | Buy → Buy | — | $6.56 | $6.60 | +0.6% | -9.5% | -1.3% | +0.3% | -50.7% | -34.1% |
| Mar 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.15 | $6.35 | +3.3% | +0.8% | +3.2% | +4.4% | -1.8% | -9.5% |
| Mar 4 | Needham | Maintains | Buy → Buy | — | $6.15 | $7.68 | +24.9% | +0.0% | +0.8% | +3.2% | +4.4% | -1.8% |
| Feb 1 | Needham | Maintains | Buy → Buy | — | $5.87 | $5.98 | +1.9% | -2.0% | -1.7% | -2.3% | +3.3% | +4.9% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.82 | $9.83 | +0.1% | +1.8% | +0.0% | +0.0% | +1.5% | -4.9% |
| Aug 7 | Chardan Capital | Maintains | Buy → Buy | — | $10.44 | $10.44 | +0.0% | -5.9% | +1.8% | +0.0% | +0.0% | +1.5% |
| Aug 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.25 | $10.28 | +0.3% | +1.9% | -5.9% | +1.8% | +0.0% | +0.0% |
| Apr 19 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $13.36 | $14.19 | +6.2% | -3.2% | -8.7% | -3.2% | +0.8% | -12.0% |
| Apr 19 | Mizuho | Upgrade | Neutral → Buy | — | $13.36 | $14.19 | +6.2% | -3.2% | -8.7% | -3.2% | +0.8% | -12.0% |
| Apr 19 | Chardan Capital | Maintains | Buy → Buy | — | $13.36 | $14.19 | +6.2% | -3.2% | -8.7% | -3.2% | +0.8% | -12.0% |
| Apr 18 | Chardan Capital | Maintains | Buy → Buy | — | $12.19 | $11.44 | -6.2% | +9.6% | -3.2% | -8.7% | -3.2% | +0.8% |
| Mar 30 | Mizuho | Maintains | Neutral → Neutral | — | $9.72 | $9.77 | +0.5% | +2.5% | -2.5% | -4.8% | -10.5% | +1.1% |
| Mar 7 | Chardan Capital | Maintains | Buy → Buy | — | $5.19 | $5.03 | -3.1% | +6.2% | +22.9% | +5.5% | +5.5% | +6.2% |
| Feb 3 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $4.18 | $4.25 | +1.7% | -5.0% | -2.3% | +5.4% | -3.9% | -3.1% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.56 | $7.68 | +1.6% | -4.0% | +1.7% | +4.2% | -1.6% | -1.8% |
| Jul 8 | Chardan Capital | Maintains | Buy → Buy | — | $5.65 | $5.87 | +3.9% | +28.8% | -3.7% | -2.0% | -0.1% | +10.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 | Zeskind Benjamin J.Dir/Off | PRESIDENT AND CEO | Buy | 2,400 | $4.56 | $11K | 2,315,252 | -1.52% | — |
| Jun 15, 2026 | Hall Brett MatthewOff | CHIEF SCIENTIFIC OFFICER | Buy | 6,035 | $4.15 | $25K | 382,531 | +7.56% | +1.32% |
8-K · 5.02
!!! Very High
Immuneering Corporation -- 8-K 5.02: Executive Change
Immuneering Corporation (IMRX) appointed Andrew Gengos as Chief Financial Officer and Senior Vice President, signaling leadership strengthening in financial management.
Jun 15
8-K
Immuneering Corporation -- 8-K Filing
I cannot provide a meaningful analysis because the summary contains only boilerplate SEC filing language without substantive information about a material event affecting Immuneering Corporation (IMRX).
Jun 11
8-K · 8.01
!! High
Immuneering Corporation -- 8-K 8.01: Material Event / Announcement
Immuneering announced positive Phase 2a data showing 17.3-month median overall survival for atebimetinib combined with chemotherapy in pancreatic cancer, potentially strengthening its clinical pipeline and de-risking development.
Jun 1
8-K · 2.02
!! High
Immuneering Corporation -- 8-K 2.02: Earnings Results
May 15
8-K
Immuneering Corporation -- 8-K Filing
Immuneering's atebimetinib achieved 64% 12-month overall survival in first-line pancreatic cancer, substantially exceeding standard-of-care gemcitabine benchmarks, potentially supporting advanced development and commercialization prospects.
Mar 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 9,697,938 | $51M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 2,288,341 | $12M | New | Mar 2026 |
| 3 | Marshall Wace, Llp | 1,996,585 | $11M | Added | Mar 2026 |
| 4 | Morgan Stanley | 979,234 | $6M | Added | Dec 2025 |
| 5 | Millennium Management | 1,102,712 | $6M | Added | Mar 2026 |
| 6 | Citadel Advisors Llc | 447,278 | $2M | Added | Mar 2026 |
| 7 | Ubs Group Ag | 376,284 | $2M | Added | Mar 2026 |
| 8 | Vanguard Fiduciary Trust Co | 322,038 | $2M | New | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 244,771 | $1M | Added | Mar 2026 |
| 10 | Connor, Clark & Lunn Investment Management Ltd. | 132,680 | $873K | New | Dec 2025 |
| 11 | Bank Of America Corp /de/ | 150,847 | $795K | Added | Mar 2026 |
| 12 | Hightower Advisors, Llc | 111,324 | $733K | Reduced | Dec 2025 |
| 13 | Jane Street Group, Llc | 102,034 | $671K | New | Dec 2025 |
| 14 | Kingsview Wealth Management, Llc | 122,200 | $644K | Added | Mar 2026 |
| 15 | Barclays Plc | 121,978 | $643K | Reduced | Mar 2026 |
| 16 | Northern Trust Corp | 117,666 | $620K | Added | Mar 2026 |
| 17 | Hudson Bay Capital Management Lp | 84,973 | $559K | Reduced | Dec 2025 |
| 18 | Susquehanna International Group, Llp | 105,507 | $556K | Reduced | Mar 2026 |
| 19 | Renaissance Technologies Llc | 72,875 | $384K | Reduced | Mar 2026 |
| 20 | Clearstead Advisors, Llc | 60,865 | $321K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$209.5M
Enterprise Value
$36.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.14x
P/B
0.96x
P/S
—
P/FCF
-4.61x
EV/EBITDA
—
Shares Out
44.0M
Financials (TTM)
Revenue
$0
Net Income
-$54.4M
EBITDA
-$58.9M
Free Cash Flow
-$45.5M
Op Cash Flow
-$45.3M
EPS Basic
$-1.27
EPS Diluted
$-1.17
EPS Forward
$-1.35
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$232.0M
Total Liab.
$13.5M
Total Equity
$218.5M
Cash
$172.8M
LT Debt
$0
Book Value/Sh
$4.96
Debt/Equity
0.02x
Current Ratio
17.50
Quick Ratio
17.50
Returns & Growth
ROE
-25.6%
ROA
-24.1%
ROIC
-26.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
+37.8%
Price Returns
2W
+12.3%
1M
+10.1%
3M
+15.6%
6M
-24.7%
12M
+237.4%
Technicals
52W High
$9.26
52W Low
$3.04
50d MA
$4.97
200d MA
$5.75
RSI (14)
64.30
ATR (14)
$0.28
Beta
0.43
Avg Volume
2.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 25, 2026 3:22pm
· Source: financialmodelingprep.com